Skip to main content

7:00 PM US/EDT Webinar – Using ReST Treatment to Improve Intelligibility in School-Aged Children with Childhood Apraxia of Speech: An Evidenced Based Intervention

This event is on September 23, 2014 7:00pm

About this Event


McCabe webinar graphic

Date and Time

September 23, 2014 @ 7:00 PM – 8:30 PM (US/EDT.)

Overview of Webinar

ReST (Rapid Syllable Transition Training) is a new treatment for children with CAS who are attempting two (or more) syllable words and is designed to address the core features of CAS. The treatment simultaneously works on sound and lexical stress accuracy and speech smoothness and has been shown to work with children aged 4-12 when provided 2-4 times per week. This webinar will outline the research which shows the effectiveness of ReST, discuss the core components and demonstrate how to provide ReST therapy in a clinical setting. Participants will learn problem solving techniques including when to step up or step down and how to include resonance along with the other goals if required.

Learning Objectives

As a result of this Webinar, participants will be able to:

  • Describe the key components of ReST treatment.
  • Outline the reasons why more intense delivery of ReST may be preferable to less intense therapy.
  • Identify smooth productions of three syllable words from unsmooth productions.
  • Describe the ReST therapy hierarchy.

Timed Agenda

Minutes 1 – 15:  Overview of ReST and the design of the treatment, discussion of the research base which demonstrates ReST is an effective treatment.
Minutes 16 – 40:  Key components of ReST, exploration of the levels of the treatment hierarchy, discussion of how the treatment works.
Minutes 41 – 70:  Clinical applications, practice in judging key components, problem solving for clinicians.
Minutes 71 – 90:  Questions and Answers.

Registration Information


CASANA Webinar FAQs (Frequently Asked Questions)

Registration closes at midnight on September 19, 2014

Featured Speaker

Tricia McCabe

Dr. Patricia McCabe is Course Director and Associate Professor at The University of Sydney, Australia. She is a Certified Practicing Speech Pathologist and member of Speech Pathology Australia. Tricia researches and practices in the area of moderate-severe speech impairments in children. Within this she has a number of interests including (a) treatments for Childhood Apraxia of Speech (CAS) (b) the comparison of speech treatments to demonstrate relative effectiveness and efficiency and (c) the use of ultrasound for biofeedback in speech pathology. With her colleagues, Elizabeth Murray and Kirrie Ballard, she has recently completed a Randomised Control Trial comparing ReST with the Nuffield Dyspraxia Program (3rd ed). Other research projects in CAS currently underway include: Developing parent delivered interventions for children with CAS in both Australia and Canada; projects trialing computer delivered versions of ReST and NDP3; and a longitudinal study of speech development in children with early identified ASD. Tricia is particularly interested in the application of the principles of speech motor learning to new treatments for CAS particularly and articulation and voice disorders more generally. She is also interested in the application of Evidence Based Practice (EBP) in speech pathology and speech pathology service delivery innovations. Tricia also holds an Honorary Research Fellowship at the Murdoch Children’s Research Institute, Melbourne, Australia. Tricia is also a clinician in private practice in Sydney with a CAS and other speech disorders caseload.

Disclosure:  Dr. McCabe acknowledges the following funding sources for her research; the Douglas and Lola Douglas Scholarship on Child and Adolescent Health for PhD student EM; the Nadia Verrall Memorial Scholarship through Speech Pathology Australia in 2010 and Postgraduate Student Scholarship through Speech Pathology Australia in 2011 to fund post treatment assessors; and the James Kentley Memorial Scholarship and Postgraduate Research Support Schemes for travel and equipment costs. There are no other financial or non-financial relationships to disclose.